Find Funding Opportunities

This NINDS Notice of Special Interest (NOSI) announces the availability of administrative supplements to support examination of human in-vivo magnetic resonance imaging (MRI) findings of presumed vascular origin (vascular contributions to cognitive impairment and dementia, VCID) as they relate to post-mortem pathology of AD/ADRD. Of interest are brain lesions resulting from dysfunctional vasculature or vascular processes, such as white matter hyperintensities, infarcts (including cortical microinfarcts), and microbleeds, along with cellular, molecular, and in-depth post-mortem imaging and pathological data analysis.

The goals of this funding opportunity announcement (FOA) are to implement and rigorously evaluate SARS-CoV-2 rapid testing strategies in communities experiencing COVID-19 health disparities. These two-year Rapid Testing Research Projects will evaluate (1) rapid testing interventions to prevent and control COVID-19 transmission among underserved and vulnerable populations and (2) partnership-driven research to implement and evaluate rapid testing and reduce COVID-19 disparities. The funding for this program is provided from the American Rescue Plan Act of 2021, PL 117-2.

The purpose of this notice is to inform applicants of a change to the key dates for RFA-NS-21-010 "HEAL Initiative: Non-addictive Analgesic Therapeutics Development [Small Molecules and Biologics] to Treat Pain (UG3/UH3 Clinical Trial Optional)". This FOA will be extended by two additional council rounds.

The purpose of this Funding Opportunity Announcement (FOA) is to invite new cooperative agreement applications for the Data Management and Coordinating Center (DMCC), which supports the Myalgic Encephalomyelitis/Chronic Fatigue Syndrome (ME/CFS) Collaborative Research Centers (CRC). This FOA will support the DMCC (U24) cooperative agreement that will focus on providing the infrastructure and support to the individual ME/CFS CRCs in their activities. Data management for efficient data collection as well as data mining and data sharing will be addressed in the data management and coordinating center (DMCC), as well as coordination of tools to identify and access available ME/CFS biospecimens. The ME/CFS CRCs will establish a network to facilitate research through: 1) collaborative basic and/or clinical research on ME/CFS; 2) provide and maintain tools for data and biospecimen sharing; 3) access to information related to ME/CFS for basic and clinical researchers, academic and practicing physicians, healthcare professionals, patients, and the lay public; and 4) facilitation of community outreach and engagement in the research activities.

This Funding Opportunity Announcement (FOA) invites applications for Myalgic Encephalomyelitis/Chronic Fatigue Syndrome (ME/CFS) Collaborative Research Centers (CRC). The overarching goal of this initiative is to establish a network of Centers that will work collaboratively to define the cause(s) of and discover improved treatments for ME/CFS. A more immediate goal for each Center is to rapidly advance synergistic, interdisciplinary research programs while serving as local resources and national leaders in ME/CFS research. Successful CRC research programs will facilitate research in ME/CFS through conducting of 1) collaborative basic and/or clinical research on ME/CFS; 2) longitudinal studies of individuals with ME/CFS within each ME/CFS CRC and across CRCs within the network; 3) access to information related to ME/CFS for basic and clinical researchers, academic and practicing physicians, healthcare professionals, patients, and the lay public. Clinical data and biospecimen sharing are required, and data management for efficient data collection and data sharing, as well as biospecimen sharing will be addressed through the separate data management and coordinating center (DMCC). Institutions must be committed to the establishment and continuation of the proposed ME/CFS CRC. Funding decisions will focus on those applications most likely to make highly impactful contributions to ME/CFS research, as well as on those with the greatest potential to collaborate effectively across the ME/CFS CRC program.

This funding opportunity announcement (FOA) provides support to eligible, domestic institutions to develop and implement effective, approaches to biomedical research education and mentoring that will keep pace with the rapid evolution of the research enterprise. This NIH Neuroscience Doctoral Readiness Program (DR Program) expects that the proposed research education programs will incorporate extensive research experiences within the NINDS mission and well-designed courses for skills development and education to prepare recent baccalaureates from diverse backgrounds to transition into and complete rigorous, research-focused doctoral degree programs (e.g., Ph.D. or M.D./Ph.D.) in biomedical fields. This is a limited competition funding opportunity announcement to support postbaccalaureate programs that will be affiliated with a funded NIH T32 program. Eligibility is limited to PD(s)/PI(s) or MPI teams that include at least one PD/PI of a grant supported by the following FOAs: T32 - Jointly Sponsored Institutional Predoctoral Training Program (JSPTPN), PAR-20-076;NINDS T32 - Institutional Research Training Grant, PAR-21-149; or NINDS T32 - Institutional Translational Research Training Program, PAR-19-228. In all cases, a PD/PI of the T32 grant from a FOA cited above, must be the PD/PI or an MPI of this R25. This Funding Opportunity Announcement (FOA) does not allow appointed participants to lead an independent clinical trial but does allow them to obtain research experience in a clinical trial led by a mentor or co-mentor.

The purpose of this Funding Opportunity Announcement (FOA) is to promote the discovery of strong candidate biomarkers or biomarker signatures for pain that can be used to facilitate the testing of non-opioid pain therapeutics in Phase II clinical trials.The biomarkers or biomarker signature will be developed through clinical research specifically focused on the identification of pain biomarkers or biosignatures that predict and/or monitor response to pain therapeutics. The resulting biomarkers or biomarker signatures may be focused on a single pain condition or on several pain conditions with common underlying pathophysiology. Applications to identify biomarkers or biomarker signatures that predict or monitor a therapeutic response across several related pain conditions should feature Multiple Principal Investigator (MPI)-led teams that represent each of the related pain conditions and associated clinical networks. The MPI-led teams are expected to decide upon a single set of measures or biomarker modalities (i.e., combination of omics, QST, actigraphy, EEG, digital measures, etc.) as components of the biosignature for all pain conditions represented in the application. Applications should feature centralized resource groups that will coordinate clinical trials and standardize all sample or data collection methods, technology development, statistical analysis and algorithm development across the pain conditions under investigation. Applications seeking to develop biomarkers or biomarker signatures that will be used to predict and/or monitor a therapeutic response for a single pain condition must also feature MPI-led teams that represent the cross functional expertise necessary for biomarker and/or signature development, along with the same types of centralized resource groups that coordinate clinical trials and standardize sample or data collection methods, technology development and statistical analysis.

This Notice of Special Interest (NOSI) provides an opportunity for clinical trials funded by the Helping to End Addiction Long-term (HEAL) initiative to address challenges of recruiting and engaging the diverse populations suffering from pain and opioid use disorder. NIH will support supplements to current HEAL awards that would either enhance their patient, community, and other stakeholder engagement efforts; improve diversity and inclusion among participants; or both, as appropriate for a particular study. The NIH HEAL Initiative is a trans-agency effort to speed scientific solutions to stem the national opioid public health crisis through understanding, managing, and treating pain and improving treatment for opioid use disorder and overdose. This supplement program is not intended to support research on basic processes but rather to implement strategies to enhance stakeholder engagement and diversity of patient inclusion in HEAL clinical studies.

This Notice announces the continuing availability of administrative supplements to active awards that focus on biomedical software development or have a significant software development component. The goal of these supplements is to invest in research software tools with recognized value in a scientific community to enhance their impact by leveraging best practices and design principles in software development and advances in technology including cloud computing. This initiative is part of a plan for implementing the NIH Strategic Plan for Data Science which describes actions aimed at modernizing the biomedical research data ecosystem to make data findable, accessible, interoperable, and reusable (FAIR) and provide robust, scalable, sustainable tools and workflows with high impact for open science. The supplements are intended to support and encourage collaborations between biomedical scientists and software engineers to enhance the design, implementation, and cloud-readiness of research software. Through these awards, the NIH Office of Data Science Strategy (ODSS) intends to help researchers who have developed scientifically valuable software to make their tools robust and sustainable, take advantage of new data science, software engineering, and computing paradigms, reach a broader community and contribute to open science.

The purpose of this funding opportunity announcement is to support research that uses human tissue or cells to generate comprehensive datasets for the discovery and characterization of functional genetic elements, epigenetic signatures, and molecular/cellular pathways that underlie human pain transduction, transmission, and processing. This FOA will support concerted multidisciplinary team science efforts that apply large-scale high-throughput approaches on tissues involved in human pain processing as part of the NIH HEAL Initiatives Program to Reveal and Evaluate Cells-to-gene Information that Specify Intricacies, Origins, and the Nature of Human Pain (PRECISION Human Pain). U19 Centers will operate as a cooperative network to promote collaboration and coordination of research activities. U19 Centers will also coordinate with the U24 HEAL Initiative: Human Pain-associated Genes and Cells Data Coordination and Integration Center in order to curate, harmonize, and integrate datasets generated by this U19 research program.